Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and management of chronic kidney disease (CKD) in adults and children.

Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Semaglutide is a glucagon-like peptide ... and death from cardiovascular causes in patients with T2D and chronic kidney disease (CKD). 10 Semaglutide is commercially available under three separate ...

Some studies sponsored by Novo Nordisk suggest that semaglutide may actually help reduce the risk of kidney disease over the ... including worsening chronic kidney failure, especially if ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Semaglutide was a top-selling drug in 2023 ... and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic’s parent company, Novo Nordisk, is the only pharmaceuti ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...